Sign in to view content

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

David M. Brown, MD

Video
Published 2021

Related

Outcomes of Intravitreal Antivascular Endothelial Growth Factor (VEGF) Therapy for Diabetic Macular Edema in Routine Clinical Practice
John D Pitcher, MD
Annual Meeting Talks
2018
Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2025
High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Annual Meeting Talks
2020

Category: Pharmacology

See more